Olema Oncology to Participate in Upcoming Investor Conferences - Olema Pharmaceuticals ( NASDAQ:OLMA )
SAN FRANCISCO, Aug. 20, 2025 ( GLOBE NEWSWIRE ) -- Olema Pharmaceuticals, Inc. ( ( "Olema", or "Olema Oncology", NASDAQ:OLMA ) , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today ...
Olema Oncology to Participate in Upcoming Investor Conferences
SAN FRANCISCO, Aug. 20, 2025 ( GLOBE NEWSWIRE ) -- Olema Pharmaceuticals, Inc. ( "Olema", or "Olema Oncology", Nasdaq: OLMA ) , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today ...
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
SAN FRANCISCO, Aug. 04, 2025 ( GLOBE NEWSWIRE ) -- Olema Pharmaceuticals, Inc. ( "Olema" or "Olema Oncology", Nasdaq: OLMA ) , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today ...
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
SAN FRANCISCO, July 02, 2025 ( GLOBE NEWSWIRE ) -- Olema Pharmaceuticals, Inc. ( "Olema" or "Olema Oncology", Nasdaq: OLMA ) , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today ...
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - Olema Pharmaceuticals ( NASDAQ:OLMA )
SAN FRANCISCO, July 02, 2025 ( GLOBE NEWSWIRE ) -- Olema Pharmaceuticals, Inc. ( ( "Olema" or "Olema Oncology", NASDAQ:OLMA ) , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today ...
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
SAN FRANCISCO, June 03, 2025 ( GLOBE NEWSWIRE ) -- Olema Pharmaceuticals, Inc. ( "Olema" or "Olema Oncology", Nasdaq: OLMA ) , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today ...
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - Olema Pharmaceuticals ( NASDAQ:OLMA )
SAN FRANCISCO, June 03, 2025 ( GLOBE NEWSWIRE ) -- Olema Pharmaceuticals, Inc. ( ( "Olema" or "Olema Oncology", NASDAQ:OLMA ) , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today ...
Olema Oncology Announces Palazestrant Dose Selection and Trial-in-Progress Poster at ASCO 2025 Annual Meeting - Olema Pharmaceuticals ( NASDAQ:OLMA )
90 mg once-daily palazestrant dose selected for Part 2 of the Phase 3 OPERA-01 monotherapy trial and for the Phase 3 OPERA-02 combination trial with ribociclib OPERA-01 trial-in-progress poster to be presented on Monday, June 2 between 9:00am-12:00pm CT / 10:00am-1:00pm ET
Olema Oncology to Participate in Upcoming Investor Conferences
SAN FRANCISCO, May 21, 2025 ( GLOBE NEWSWIRE ) -- Olema Pharmaceuticals, Inc. ( "Olema" or "Olema Oncology", Nasdaq: OLMA ) , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today ...
Wall Street Analysts See a 386.42% Upside in Olema Pharmaceuticals ( OLMA ) : Can the Stock Really Move This High?
The consensus price target hints at a 386.4% upside potential for Olema Pharmaceuticals (OLMA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Olema Oncology to Participate in Upcoming Investor Conferences
SAN FRANCISCO, May 09, 2025 ( GLOBE NEWSWIRE ) -- Olema Pharmaceuticals, Inc. ( "Olema", "Olema Oncology", Nasdaq: OLMA ) a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced ...
Olema Oncology to Participate in Upcoming Investor Conferences - Olema Pharmaceuticals ( NASDAQ:OLMA )
SAN FRANCISCO, May 09, 2025 ( GLOBE NEWSWIRE ) -- Olema Pharmaceuticals, Inc. ( ( "Olema", "Olema Oncology", NASDAQ:OLMA ) a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced ...
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
SAN FRANCISCO, May 02, 2025 ( GLOBE NEWSWIRE ) -- Olema Pharmaceuticals, Inc. ( "Olema" or "Olema Oncology", Nasdaq: OLMA ) , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today ...
Wall Street Analysts Think Olema Pharmaceuticals ( OLMA ) Could Surge 433.13%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 433.1% in Olema Pharmaceuticals (OLMA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the ...
After Plunging -30.16% in 4 Weeks, Here's Why the Trend Might Reverse for Olema Pharmaceuticals ( OLMA )
The heavy selling pressure might have exhausted for Olema Pharmaceuticals (OLMA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend ...
Why Sangamo Therapeutics Shares Are Trading Higher By Around 40%; Here Are 20 Stocks Moving Premarket - Compass Minerals Intl ( NYSE:CMP ) , Adaptive Biotechnologies ( NASDAQ:ADPT )
Shares of Sangamo Therapeutics, Inc. SGMO rose sharply in today's pre-market trading after the company announced a new agreement with pharmaceutical giant Eli Lilly And Co LLY, granting the company a worldwide exclusive license to leverage the company's novel proprietary neurotropic ...
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
SAN FRANCISCO, April 02, 2025 ( GLOBE NEWSWIRE ) -- Olema Pharmaceuticals, Inc. ( "Olema" or "Olema Oncology", Nasdaq: OLMA ) , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today ...
Li Auto, Xponential Fitness And Other Big Stocks Moving Lower In Friday's Pre-Market Session - EyePoint Pharmaceuticals ( NASDAQ:EYPT ) , Cormedix ( NASDAQ:CRMD )
U.S. stock futures were higher this morning, with the Dow futures gaining around 150 points on Friday. Shares of Li Auto Inc. LI fell sharply in today's pre-market trading after the company reported fourth-quarter results. Li Auto posted quarterly adjusted EPADS of 52 cents, up from 30 cents in ...
Why Rubrik Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket - Applied Optoelectronics ( NASDAQ:AAOI ) , Bit Origin ( NASDAQ:BTOG )
Shares of Rubrik, Inc. RBRK rose sharply in today's pre-market trading after the company reported better-than-expected fourth-quarter financial results and issued first-quarter guidance above estimates. Rubrik reported quarterly losses of 61 cents per share, which beat the analyst consensus ...
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
SAN FRANCISCO, March 04, 2025 ( GLOBE NEWSWIRE ) -- Olema Pharmaceuticals, Inc. ( "Olema" or "Olema Oncology", Nasdaq: OLMA ) , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today ...
Olema Oncology to Present at the TD Cowen 45th Annual Health Care Conference
SAN FRANCISCO, Feb. 19, 2025 ( GLOBE NEWSWIRE ) -- Olema Pharmaceuticals, Inc. ( "Olema" or "Olema Oncology", Nasdaq: OLMA ) , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today ...
Olema Oncology to Present at the TD Cowen 45th Annual Health Care Conference - Olema Pharmaceuticals ( NASDAQ:OLMA )
SAN FRANCISCO, Feb. 19, 2025 ( GLOBE NEWSWIRE ) -- Olema Pharmaceuticals, Inc. ( ( "Olema" or "Olema Oncology", NASDAQ:OLMA ) , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today ...
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule ...
Olema Oncology to Participate in Upcoming Investor Conferences
SAN FRANCISCO, Feb. 03, 2025 ( GLOBE NEWSWIRE ) -- Olema Pharmaceuticals, Inc. ( "Olema" or "Olema Oncology", Nasdaq: OLMA ) , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today ...
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
SAN FRANCISCO, Jan. 03, 2025 ( GLOBE NEWSWIRE ) -- Olema Pharmaceuticals, Inc. ( "Olema" or "Olema Oncology", Nasdaq: OLMA ) , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today ...
Olema Oncology to Present at 43rd Annual J.P. Morgan Healthcare Conference
SAN FRANCISCO, Jan. 02, 2025 ( GLOBE NEWSWIRE ) -- Olema Pharmaceuticals, Inc. ( "Olema" or "Olema Oncology", Nasdaq: OLMA ) , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today ...
Olema Oncology to Present at 43rd Annual J.P. Morgan Healthcare Conference - Olema Pharmaceuticals ( NASDAQ:OLMA )
SAN FRANCISCO, Jan. 02, 2025 ( GLOBE NEWSWIRE ) -- Olema Pharmaceuticals, Inc. ( ( "Olema" or "Olema Oncology", NASDAQ:OLMA ) , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today ...
Novartis' Gene Therapy Meets Primary Endpoint in SMA Study
NVS' phase III study on experimental gene therapy candidate Intrathecal onasemnogene abeparvovec (OAV101IT) meets its primary goal.
Top 3 Health Care Stocks That May Explode In Q4 - ModivCare ( NASDAQ:MODV ) , Olema Pharmaceuticals ( NASDAQ:OLMA )
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down.
Olema Oncology Presents Updated Clinical Results for Palazestrant in Combination with Ribociclib at the San Antonio Breast Cancer Symposium
SAN FRANCISCO, Dec. 10, 2024 ( GLOBE NEWSWIRE ) -- Olema Pharmaceuticals, Inc. ( "Olema" or "Olema Oncology", Nasdaq: OLMA ) , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today ...
Novartis Announces Positive Results From Late-Stage Study on Fabhalta
NVS' Fabhalta improves the average hemoglobin level compared to baseline in adult patients with PNH who switched from anti-C5 therapies.
Olema Oncology Announces FDA Clearance of Investigational New Drug Application for OP-3136, a Potent KAT6 Inhibitor - Olema Pharmaceuticals ( NASDAQ:OLMA )
Phase 1 clinical trial for OP-3136 to initiate in early 2025 SAN FRANCISCO, Dec. 09, 2024 ( GLOBE NEWSWIRE ) -- Olema Pharmaceuticals, Inc. ( ( "Olema" or "Olema Oncology", NASDAQ:OLMA ) , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of ...
Olema Oncology Announces FDA Clearance of Investigational New Drug Application for OP-3136, a Potent KAT6 Inhibitor
SAN FRANCISCO, Dec. 09, 2024 ( GLOBE NEWSWIRE ) -- Olema Pharmaceuticals, Inc. ( "Olema" or "Olema Oncology", Nasdaq: OLMA ) , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today ...
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
SAN FRANCISCO, Dec. 03, 2024 ( GLOBE NEWSWIRE ) -- Olema Pharmaceuticals, Inc. ( "Olema" or "Olema Oncology", Nasdaq: OLMA ) , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today ...
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - Olema Pharmaceuticals ( NASDAQ:OLMA )
SAN FRANCISCO, Dec. 03, 2024 ( GLOBE NEWSWIRE ) -- Olema Pharmaceuticals, Inc. ( ( "Olema" or "Olema Oncology", NASDAQ:OLMA ) , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today ...
Novartis In-Licenses PTCT's Huntington's Disease Drug for $2.9 Billion
NVS is all set to strengthen its neuroscience pipeline with the addition of PTCT's Huntington's disease drug.
Olema Oncology Announces New Clinical Trial Collaboration and Supply Agreement with Novartis in Frontline Metastatic Breast Cancer as well as $250 Million Equity Private Placement - Olema Pharmaceuticals ( NASDAQ:OLMA )
Clinical trial collaboration and supply agreement enables pivotal Phase 3 OPERA-02 clinical trial of palazestrant in combination with ribociclib in frontline ER+/HER2- metastatic breast cancer; trial initiation expected in mid-2025
Olema Oncology to Present New Data Combining Palazestrant with Ribociclib at the San Antonio Breast Cancer Symposium
Olema will host an investor conference call at 8:00 a.m. ET on December 10, 2024 Olema will host an investor conference call at 8:00 a.m. ET on December ...
Olema Oncology to Participate in Upcoming Investor Conferences - Olema Pharmaceuticals ( NASDAQ:OLMA )
SAN FRANCISCO, Nov. 06, 2024 ( GLOBE NEWSWIRE ) -- Olema Pharmaceuticals, Inc. ( ( "Olema", "Olema Oncology", NASDAQ:OLMA ) , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today ...
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - Olema Pharmaceuticals ( NASDAQ:OLMA )
SAN FRANCISCO, Nov. 04, 2024 ( GLOBE NEWSWIRE ) -- Olema Pharmaceuticals, Inc. ( ( "Olema" or "Olema Oncology", NASDAQ:OLMA ) , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today ...
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
SAN FRANCISCO, Nov. 04, 2024 ( GLOBE NEWSWIRE ) -- Olema Pharmaceuticals, Inc. ( "Olema" or "Olema Oncology", Nasdaq: OLMA ) , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today ...
Olema Oncology Presents Compelling New Preclinical Data Demonstrating Anti-Tumor Activity for OP-3136 with Enhanced Activity of Palazestrant Combinations at ENA 2024
SAN FRANCISCO, Oct. 23, 2024 ( GLOBE NEWSWIRE ) -- Olema Pharmaceuticals, Inc. ( "Olema" or "Olema Oncology", Nasdaq: OLMA ) , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today ...
Why Intuitive Surgical Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket - Akanda ( NASDAQ:AKAN ) , Cemtrex ( NASDAQ:CETX )
Shares of Intuitive Surgical, Inc. ISRG rose sharply in today's pre-market trading as the company posted better-than-expected third-quarter financial results. The company also said it obtained regulatory clearance in South Korea for the da Vinci 5 surgical system in October.
Olema Oncology Announces New Preclinical Combination Data to be Presented at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics - Olema Pharmaceuticals ( NASDAQ:OLMA )
SAN FRANCISCO, Oct. 09, 2024 ( GLOBE NEWSWIRE ) -- Olema Pharmaceuticals, Inc. ( ( "Olema" or "Olema Oncology", NASDAQ:OLMA ) , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women's cancers, today announced that ...
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
SAN FRANCISCO, Oct. 02, 2024 ( GLOBE NEWSWIRE ) -- Olema Pharmaceuticals, Inc. ( "Olema" or "Olema Oncology", Nasdaq: OLMA ) , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women's cancers, today announced that ...
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - Olema Pharmaceuticals ( NASDAQ:OLMA )
SAN FRANCISCO, Oct. 02, 2024 ( GLOBE NEWSWIRE ) -- Olema Pharmaceuticals, Inc. ( ( "Olema" or "Olema Oncology", NASDAQ:OLMA ) , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women's cancers, today announced that ...
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
SAN FRANCISCO, Sept. 04, 2024 ( GLOBE NEWSWIRE ) -- Olema Pharmaceuticals, Inc. ( "Olema" or "Olema Oncology", Nasdaq: OLMA ) , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women's cancers, today announced that ...
Olema Oncology to Participate in Morgan Stanley 22nd Annual Global Healthcare Conference
SAN FRANCISCO, Aug. 21, 2024 ( GLOBE NEWSWIRE ) -- Olema Pharmaceuticals, Inc. ( "Olema", "Olema Oncology", Nasdaq: OLMA ) , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women's cancers, today announced that its ...
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
SAN FRANCISCO, Aug. 02, 2024 ( GLOBE NEWSWIRE ) -- Olema Pharmaceuticals, Inc. ( "Olema" or "Olema Oncology", Nasdaq: OLMA ) , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women's cancers, today announced that ...
Olema Pharmaceuticals Clears Key Benchmark, Hitting 90-Plus RS Rating
Olema Pharmaceuticals ( OLMA ) saw a welcome improvement to its Relative Strength ( RS ) Rating on Wednesday, with an increase from 87 to 91. ↑ X How To Buy Stocks: Do You Know Your Stock's Personality Type? NOW PLAYING How To Buy Stocks: Do You Know Your Stock's Personality Type?
